Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity

Brum,Mariana Concentino Menezes; Dos Santos Guimaraes,Isabella; Ferreira,Luciana Bueno; Rangel,Leticia Batista Azevedo; Maia,Raquel Ciuvalschi; Nestal De Moraes,Gabriela; Gimba,Etel R.P.

doi:10.3892/or.2020.7877

Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity

Authors:
- Mariana Concentino Menezes Brum
- Isabella Dos Santos Guimaraes
- Luciana Bueno Ferreira
- Leticia Batista Azevedo Rangel
- Raquel Ciuvalschi Maia
- Gabriela Nestal De Moraes
- Etel R.P. Gimba
View Affiliations

Affiliations: Program of Molecular and Cellular Oncobiology, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil, Division of Clinical Research, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil, Departament of Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Espírito Santo 29040‑090, Brazil, Stricto Sensu Graduate Program in Oncology, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil
Published online on: December 1, 2020 https://doi.org/10.3892/or.2020.7877
Pages: 652-664
Copyright: © Brum et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteopontin (OPN) is upregulated in several types of tumor and has been associated with chemoresistance. However, the contribution of OPN splicing isoforms (OPN‑SIs) to chemoresistance requires further investigation. The present study aimed to evaluate the expression patterns of each tested OPN‑SI in cisplatin (CDDP)‑resistant ovarian carcinoma cell lines, focusing on the role of the OPN‑c isoform (OPNc) in drug resistance. ACRP ovarian cancer cells resistant to CDDP, as well as their parental cell line A2780, were used. Analyses of the transcriptional expression of OPN‑SIs, epithelial‑mesenchymal transition (EMT) markers and EMT‑related cytokines were performed using reverse transcription‑quantitative PCR. OPNc was silenced in ACRP cells using anti‑OPNc DNA oligomers and stably overexpressed by transfecting A2780 cells with a mammalian expression vector containing the full length OPNc cDNA. Functional assays were performed to determine cell proliferation, viability and colony formation. The results demonstrated that among the three tested OPN‑SIs, OPNc was the most upregulated transcript in the ACRP cells compared with the parental A2780 cells. In addition, the expression levels of P‑glycoprotein multidrug transporter were upregulated in CDDP‑resistant ACRP cells compared with those in A2780 cells. OPNc knockdown sensitized ACRP cells to CDDP treatment and downregulated P‑gp expression levels compared with those in the negative control group. Additionally, silencing of OPNc impaired cell proliferative and colony formation abilities, as well as reversed the expression levels of EMT markers and EMT‑related cytokines compared with those in the negative control cells. Notably, although stable OPNc overexpression resulted in increased A2780 cell proliferation, it notably increased CDDP sensitivity compared with that in the cells transfected with a control vector. These results suggested that OPNc silencing may represent a putative approach to sensitize resistant ovarian cancer cells to chemotherapeutic agents.

View Figures

View References

1	International Agency for Research on Cancer (IARC). Global Cancer Observatory. IARC; Lyon: 2020, simplehttps://gco.iarc.fr/
2	Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA and Cottrill HM: A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 34:1032017. View Article : Google Scholar : PubMed/NCBI
3	Freimund AE, Beach JA, Christie EL and Bowtell DDL: Mechanisms of drug resistance in high-grade serous ovarian cancer. Hematol Oncol Clin North Am. 32:983–996. 2018. View Article : Google Scholar : PubMed/NCBI
4	Gottesman MM, Lavi O, Hall MD and Gillet JP: Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol. 56:85–102. 2016. View Article : Google Scholar : PubMed/NCBI
5	Pandey MK, Prasad S, Tyagi AK, Deb L, Huang J, Karelia DN, Amin SG and Aggarwal BB: Targeting cell survival proteins for cancer cell death. Pharmaceuticals (Basel). 9:112016. View Article : Google Scholar
6	Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yang RS and Fu WM: Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol. 83:968–977. 2013. View Article : Google Scholar : PubMed/NCBI
7	Du B and Shim JS: Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 21:9652016. View Article : Google Scholar
8	Elaskalani O, Razak NBA, Falasca M and Metharom P: Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer. World J Gastrointest Oncol. 9:37–41. 2017. View Article : Google Scholar : PubMed/NCBI
9	He Y, Xie H, Yu P, Jiang S and Wei L: FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells. Cancer Chemother Pharmacol. 82:1049–1059. 2018. View Article : Google Scholar : PubMed/NCBI
10	Gimba ERP, Brum MCM and Nestal De Moraes G: Full-length osteopontin and its splice variants as modulators of chemoresistance and radioresistance (Review). Int J Oncol. 54:420–430. 2019.PubMed/NCBI
11	Ding K, Fan L, Chen S, Wang Y, Yu H, Sun Y, Yu J, Wang L, Liu X and Liu Y: Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC. Oncol Rep. 34:3297–3303. 2015. View Article : Google Scholar : PubMed/NCBI
12	Grbčić P, Tomljanović I, Klobučar M, Kraljević Pavelić S, Lučin K and Sedić M: Dual sphingosine kinase inhibitor SKI–II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling. Biochem Biophys Res Commun. 487:782–788. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, Yau TC, Lo O, Foo CC, Poon JT, et al: Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int. 2015:2478922015. View Article : Google Scholar : PubMed/NCBI
14	Pang H, Cai L, Yang Y, Chen X, Sui G and Zhao C: Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother Radiopharm. 26:165–173. 2011. View Article : Google Scholar : PubMed/NCBI
15	Qian C, Li P, Yan W, Shi L, Zhang J, Wang Y, Liu H and You Y: Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl-2 pathway. Mol Med Rep. 11:1951–1955. 2015. View Article : Google Scholar : PubMed/NCBI
16	Gimba ER and Tilli TM: Human osteopontin splicing isoforms: Known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 331:11–17. 2013. View Article : Google Scholar : PubMed/NCBI
17	Hui T, Sørensen ES and Rittling SR: Osteopontin binding to the alpha 4 integrin requires highest affinity integrin conformation, but is independent of post-translational modifications of osteopontin. Matrix Biol. 41:19–25. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kazanecki CC, Uzwiak DJ and Denhardt DT: Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 102:912–924. 2007. View Article : Google Scholar : PubMed/NCBI
19	Nakamura KDM, Tilli TM, Wanderley JL, Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE, Nasciutti LE and Gimba ER: Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumour Biol. 37:2655–2663. 2016. View Article : Google Scholar : PubMed/NCBI
20	Bastos ACSF, Blunck CB, Emerenciano M and Gimba ERP: Osteopontin and their roles in hematological malignancies: Splice variants on the new avenues. Cancer Lett. 408:138–143. 2017. View Article : Google Scholar : PubMed/NCBI
21	Santoro JC, Bastos ACSF, Gimba ERP and Emerenciano M: Reinforcing osteopontin as a marker of central nervous system relapse in paediatric B-cell acute lymphoblastic leukaemia: SPP1 splice variant 3 in the spotlight. Br J Haematol. 186:e88–e91. 2019. View Article : Google Scholar : PubMed/NCBI
22	Sherman-Baust CA, Weeraratna AT, Rangel LBA, Pizer ES, Cho KR, Schwartz DR, Shock T and Morin PJ: Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 3:377–386. 2003. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Yosifov DY, Reufsteck C, Konstantinov SM and Berger MR: Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines. Leuk Res. 36:764–772. 2012. View Article : Google Scholar : PubMed/NCBI
25	Caldwell JT, Edwards H, Dombkowski AA, Buck SA, Matherly LH, Ge Y and Taub JW: Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. PLoS One. 8:e686012013. View Article : Google Scholar : PubMed/NCBI
26	Niu ZH, Wang Y, Chun B, Li CX and Wu L: Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. Eur Rev Med Pharmacol Sci. 17:1337–1344. 2013.PubMed/NCBI
27	Wilks ST: Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway. Breast. 24:548–555. 2015. View Article : Google Scholar : PubMed/NCBI
28	Montazami N, Aghapour M, Farajnia S and Baradaran B: New insights into the mechanisms of multidrug resistance in cancers. Cell Mol Biol (Noisy-le-grand). 61:70–80. 2015.PubMed/NCBI
29	Yang X, Yi C, Luo N and Gong C: Nanomedicine to overcome cancer multidrug resistance. Curr Drug Metab. 15:632–649. 2014. View Article : Google Scholar : PubMed/NCBI
30	Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF and Gimba ER: Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 9:280–293. 2011. View Article : Google Scholar : PubMed/NCBI
31	Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
32	Zhou B, Sun C, Li N, Shan W, Lu H, Guo L, Guo E, Xia M, Weng D, Meng L, et al: Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways. Int J Oncol. 48:2087–2097. 2016. View Article : Google Scholar : PubMed/NCBI
33	Kothari AN, Arffa ML, Chang V, Blackwell RH, Syn WK, Zhang J, Mi Z and Kuo PC: Osteopontin-A Master Regulator of Epithelial-Mesenchymal Transition. J Clin Med. 5:52016. View Article : Google Scholar
34	Zhu Y, Gao XM, Yang J, Xu D, Zhang Y, Lu M, Zhang Z, Sheng YY, Li JH, Yu XX, et al: C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Sci. 109:710–723. 2018. View Article : Google Scholar : PubMed/NCBI
35	Breier A, Gibalova L, Seres M, Barancik M and Sulova Z: New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem. 13:159–170. 2013. View Article : Google Scholar : PubMed/NCBI
36	Munoz JL, Walker ND, Scotto KW and Rameshwar P: Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 367:69–75. 2015. View Article : Google Scholar : PubMed/NCBI
37	Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE and Gottesman MM: Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018. View Article : Google Scholar : PubMed/NCBI
38	Luo SD, Chen YJ, Liu CT, Rau KM, Chen YC, Tsai HT, Chen CH and Chiu TJ: Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. BioMed Res Int. 2015:5085872015. View Article : Google Scholar : PubMed/NCBI
39	Huang J, Chang S, Lu Y, Wang J, Si Y, Zhang L, Cheng S and Jiang WG: Enhanced osteopontin splicing regulated by RUNX2 is HDAC-dependent and induces invasive phenotypes in NSCLC cells. Cancer Cell Int. 19:3062019. View Article : Google Scholar : PubMed/NCBI
40	Davidson B, Tropé CG and Reich R: Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol. 2:332012. View Article : Google Scholar : PubMed/NCBI
41	Huang RYJ, Wong MK, Tan TZ, Kuay KT, Ng AH, Chung VY, Chu YS, Matsumura N, Lai HC, Lee YF, et al: An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 4:e9152013. View Article : Google Scholar : PubMed/NCBI
42	Chebouti I, Kasimir-Bauer S, Buderath P, Wimberger P, Hauch S, Kimmig R and Kuhlmann JD: EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. Oncotarget. 8:48820–48831. 2017. View Article : Google Scholar : PubMed/NCBI
43	Carduner L, Leroy-Dudal J, Picot CR, Gallet O, Carreiras F and Kellouche S: Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: Enhancement of their invasive behavior partly dependant on αv integrins. Clin Exp Metastasis. 31:675–688. 2014. View Article : Google Scholar : PubMed/NCBI
44	Techasen A, Loilome W, Namwat N, Dokduang H, Jongthawin J and Yongvanit P: Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells. Asian Pac J Cancer Prev. 13 (Suppl):115–118. 2012.PubMed/NCBI
45	Sistigu A, Di Modugno F, Manic G and Nisticò P: Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine Growth Factor Rev. 36:67–77. 2017. View Article : Google Scholar : PubMed/NCBI
46	Rezaeifard S, Razmkhah M, Robati M, Momtahan M and Ghaderi A: Cytokines, chemokines, and chemokine receptors quantitative expressions in patients with ovarian cancer. Iran J Med Sci. 40:225–232. 2015.PubMed/NCBI
47	Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM and Hall BM: Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 28:2940–2947. 2009. View Article : Google Scholar : PubMed/NCBI
48	Fernando RI, Hamilton DH, Huang B and Palena C: Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas. J Immunother Cancer. 1 (S1):1872013. View Article : Google Scholar
49	Zhang C, Ma K and Li WY: IL-6 promotes cancer stemness and oncogenicity in U2OS and MG-63 osteosarcoma cells by upregulating the OPN-STAT3 pathway. J Cancer. 10:6511–6525. 2019. View Article : Google Scholar : PubMed/NCBI
50	Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB and Kahlenberg MS: HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer. 103:2252–2260. 2005. View Article : Google Scholar : PubMed/NCBI
51	Omarini C, Bettelli S, Caprera C, Manfredini S, Caggia F, Guaitoli G, Moscetti L, Toss A, Cortesi L, Kaleci S, et al: Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. Cancer Biol Ther. 19:879–886. 2018. View Article : Google Scholar : PubMed/NCBI
52	Kwon MJ, Soh JS, Lim SW, Kang HS and Lim H: HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer. Pathol Res Pract. 215:910–917. 2019. View Article : Google Scholar : PubMed/NCBI
53	Gerson JN, Skariah S, Denlinger CS and Astsaturov I: Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs. 26:531–540. 2017. View Article : Google Scholar : PubMed/NCBI
54	El Dika I and Ilson DH: Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. Expert Rev Anticancer Ther. 18:1085–1092. 2018. View Article : Google Scholar : PubMed/NCBI
55	Dong Y, Li W, Gu Z, Xing R, Ma Y, Zhang Q and Liu Z: Inhibition of HER2-positive breast cancer growth by blocking the HER2 signaling pathway with HER2-glycan-imprinted nanoparticles. Angew Chem Int Ed Engl. 58:10621–10625. 2019. View Article : Google Scholar : PubMed/NCBI